Correction: Involvement of the VEGF receptor 3 in tubular morphogenesis demonstrated with a human antihuman VEGFR-3 monoclonal antibody that antagonizes receptor activation by VEGF-C (J. Cell Sci. (2004) 117 (2745–2756) DOI: 10.1242/jcs.01138);Involvement of the VEGF receptor 3 in tubular morphogenesis demonstrated with a human anti-human VEGFR-3 monoclonal antibody that antagonizes receptor activation by VEGF-C

Journal of Cell Science

Volumn 117, Issue 13, 2004, Pages 2745-2756

  Persaud, Kris ^a   Tille, Jean Christophe ^b   Liu, Meilin ^a   Zhu, Zhenping ^a   Jimenez, Xenia ^a   Pereira, Daniel S ^a   Miao, Hua Quan ^a   Brennan, Laura A ^a   Witte, Larry ^a   Pepper, Michael S ^b   Pytowski, Bronislaw ^a  

^a ELI LILLY AND COMPANY   (United States)

^b UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

Flt 4; VEGF C; VEGFR 3

Indexed keywords

GLUCOSE DEHYDROGENASE; MONOCLONAL ANTIBODY; PODOPLANIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CELL POPULATION; CELL STRUCTURE; CHEMOTAXIS; CHIMERA; CONTROLLED STUDY; DRUG RECEPTOR BINDING; ENDOTHELIUM CELL; FLUORESCENCE; HUMAN; HUMAN CELL; IMMOBILIZED CELL; IMMUNOREACTIVITY; IN VITRO STUDY; MITOGENESIS; MORPHOGENESIS; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALIA; BOVINAE;

EID: 3042587472     PISSN: 00219533     EISSN: 14779137     Source Type: Journal    
DOI: 10.1242/jcs.261562     Document Type: Erratum

References (45)

1. Byzova, T. V., Goldman, C. K., Jankau, J., Chen, J., Cabrera, G., Achen, M. G., Slacker, S. A., Carnevale, K. A., Siemionow, M., Deitcher, S. R. et al. (2002). Adenovirus encoding vascular endothelial growth factor-D induces tissue-specific vascular patterns in vivo. Blood 99, 4434-4442.
2. Can, Y., Linden, P., Farnebo, J., Cao, R., Eriksson, A., Kumar, V., Qi, J.H., Claesson-Welsh, L. and Alitalo, K. (1998). Vascular endothelial growth factor C induces angiogenesis in vivo. Proc. Natl. Acad. Sci. USA 95, 14389-14394.
3. Clarijs, R., Schalkwijk, L., Hofmann, U. B., Ruiter, D. J. and de Waal, R. M. (2002). Induction of vascular endothelial growth factor receptor-3 expression on tumor microvasculature as a new progression marker in human cutaneous melanoma. Cancer Res. 62, 7059-7065.
4. de Haard, H. J., van Neer, N., Reurs, A., Hufton, S. E., Roovers, R. C., Henderikx, P., de Bruine, A. P., Arends, J. W. and Hoogenboom, H. R. (1999). A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies. J. Biol. Chem. 274, 18218-18230.
5. Delmar, M. and Hirakawa, S. (2002). The formation of lymphatic vessels and its importance in the setting of malignancy. J. Exp. Med. 196, 713-718.
6. Dixelius, J., Makinen, T., Wirzenius, M., Karkkainen, M. J., Wernstedt, C., Alitalo, K. and Claesson-Welsh, L. (2003). Ligand-induced vascular endothelial growth factor receptor-3 (VEGFR-3) heterodimerization with VEGFR-2 in primary lymphatic endothelial cells regulates tyrosine phosphorylation sites. J. Biol. Chem. 278, 40973-40979.
7. Dumont, D. J., Jussila, L., Taipale, J., Lymboussaki, A., Mustonen, T., Pajusola, K., Breitman, M. and Alitalo, K. (1998). Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. Science 282, 946-949.
8. Flanagan, J. G. and Letter, P. (1990). The kit ligand: a cell surface molecule altered in steel mutant fibroblasts. Cell 53, 185-194.
9. Ganju, R. K., Munshi, N., Nair, B. C., Liu, Z. Y., Gill, P. and Groopman, J. E. (1998). Human immunodeficiency virus tat modulates the Flk-1/VEGFR-2 receptor, mitogen-activated protein kinases, and components of focal adhesion in Kaposi's sarcoma cells. J. Virol. 72, 6131-6137.
10. He, Y., Kozaki, K., Karpanen, T., Koshikawa, K., Yla-Herttuala, S., Takahashi, T. and Alitalo, K. (2002). Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J. Natl. Cancer Inst. 94, 819-825.
11. Jeltsch, M., Kaipainen, A., Joukov, V., Meng, X., Lakso, M., Rauvala, H., Swartz, M., Fukumura, D., Jain, R. K. and Alitalo, K. (1997). Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science 276, 1423-1425.
12. Joukov, V., Pajusola, K., Kaipainen, A., Chilov, D., Lahtinen, I., Kukk, E., Saksela, O., Kalkkinen, N. and Alitalo, K. (1996). A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and VEGFR-2 (VEGFR-2) receptor tyrosine kinases. EMBO J. 15, 290-298.
13. Joukov, V., Sorsa, T., Kumar, V., Jeltsch, M., Claesson-Welsh, L., Cao, Y., Saksela, O., Kalkkinen, N. and Alitalo, K. (1997). Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J. 16, 3898-3911.
14. Karkkainen, M. J., Ferrell, R. E., Lawrence, E. C., Kimak, M. A., Levinson, K. L., McTigue, M. A., Alitalo, K. and Finegold, D. N. (2000). Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema. Nat. Genet. 25, 153-159.
15. Karkkainen, M. J., Saaristo, A., Jussila, L., Karila, K. A., Lawrence, E. C., Pajusola, K., Bueler, H., Eichmann, A., Kauppinen, R., Kettunen, M. I. et al. (2001). A model for gene therapy of human hereditary lymphedema. Proc. Natl. Acad. Sci. USA 98, 12677-12682.
16. Karpanen, T. and Alitalo, K. (2001). Lymphatic vessels as targets of tumor therapy? J. Exp. Med. 194, F37-F42.
17. Karpanen, T., Egeblad, M., Karkkainen, M. J., Kubo, H., Yla-Herttuala, S., Jaattela, M. and Alitalo, K. (2001). Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res. 61, 1786-1790.
18. Kriehuber, E., Breiteneder-Geleff, S., Groeger, M., Suleiman, A., Schoppmann, S. F., Stingl, G., Kerjaschki, D. and Maurer, D. (2001). Isolation and characterization of dermal lymphatic and blood endothelial cells reveal stable and functionally specialized cell lineages. J. Exp. Med. 194, 797-808.
19. Kubo, H., Fujiwara, T., Jussila, L., Hashi, H., Ogawa, M., Shimizu, K., Awane, M., Sakai, Y., Takabayashi, A., Alitalo, K. et al. (2000). Involvement of vascular endothelial growth factor receptor-3 in maintenance of integrity of endothelial cell lining during tumor angiogenesis. Blood 96, 546-553.
20. Liu, Z. Y., Ganju, R. K., Wang, J. F., Ona, M. A., Hatch, W. C., Zheng, T., Avraham, S., Gill, P. and Groopman, J. F. (1997). Cytokine signaling through the novel tyrosine kinase RAFTK in Kaposi's sarcoma cells. J. Clin. Invest. 99, 1798-1804.
21. Lu, D., Kussie, P., Pytowski, B., Persaud, K., Bohlen, P., Witte, L. and Zhu, Z. (2000). Identification of the residues in the extracellular region of VEGFR-2 important for interaction with vascular endothelial growth factor and neutralizing anti-VEGFR-2 antibodies. J. Biol. Chem. 275, 14321-14330.
22. Lu, D., Jimenez, X., Zhang, H., Bohlen, P., Witte, L. and Zhu, Z. (2002). Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy. Int. J. Cancer 97, 393-399.
23. Lymboussaki, A., Partanen, T. A., Olofsson, B., Thomas-Crusells, J., Fletcher, C. D., de, W. R., Kaipainen, A. and Alitalo, K. (1998). Expression of the vascular endothelial growth factor C receptor VEGFR-3 in lymphatic endothelium of the skin and in vascular tumors. Am. J. Pathol. 153, 395-403.
24. Makinen, T., Jussila, L., Veikkola, T., Karpanen, T., Kettunen, M. I., Pulkkanen, K. J., Kauppinen, R., Jackson, D. G., Kubo, H., Nishikawa, S. et al. (2001a). Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat. Med. 7, 199-205.
25. Makinen, T., Veikkola, T., Mustjoki, S., Karpanen, T., Catimel, B., Nice, E. C., Wise, L., Mercer, A., Kowalski, H., Kerjaschki, D. et al. (2001b). Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. EMBO J. 20, 4762-4773.
26. Mandriota, S. J., Jussila, L., Jeltsch, M., Compagni, A., Baetens, D., Prevo, R., Banerji, S., Huarte, J., Montesano, R., Jackson, D. G. et al. (2001). Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J. 20, 672-682.
27. Marconcini, L., Marchio, S., Morbidelli, L., Cartocci, E., Albini, A., Ziche, M., Bussolino, F. and Oliviero, S. (1999). c-fos-induced growth factor/vascular endothelial growth factor D induces angiogenesis in vivo and in vitro. Proc. Natl. Acad. Sci. USA 96, 9671-9676.
28. Montesano, R. and Orci, L. (1985). Tumor-promoting phorbol esters induce angiogenesis in vitro. Cell 42, 469-477.
29. Partanen, T. A., Arola, J., Saaristo, A., Jussila, L., Ora, A., Miettinen, M., Stacker, S. A., Achen, M. G. and Alitalo, K. (2000). VEGF-C and VEGF-D expression in neuroendocrine cells and their receptor, VEGFR-3, in fenestrated blood vessels in human tissues. FASEB J. 14, 2087-2096.
30. Pepper, M. S., Ferrara, N., Orci, L. and Montesano, R. (1992a). Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem. Biophys. Res. Commun. 189, 824-831.
31. Pepper, M. S., Montesano, R., el Aoumari, A., Gros, D., Orci, L. and Meda, P. (1992b). Coupling and connexin 43 expression in microvascular and large vessel endothelial cells. Am. J. Physiol. 262, 1246-1257.
32. Pepper, M. S., Mandriota, S. J., Jeltsch, M., Kumar, V. and Alitalo, K. (1998). Vascular endothelial growth factor (VEGF)-C synergizes with basic fibroblast growth factor and VEGF in the induction of angiogenesis in vitro and alters endothelial cell extracellular proteolytic activity. J. Cell. Physiol. 177, 439-452.
33. Skobe, M., Hawighorst, T., Jackson, D. G., Prevo, R., Janes, L., Velasco, P., Riccardi, L., Alitalo, K., Claffey, K. and Detmar, M. (2001). Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat. Med. 7, 192-198.
34. Stacker, S. A., Caesar, C., Baldwin, M. E., Thornton, G. E., Williams, R. A., Prevo, R., Jackson, D. G., Nishikawa, S., Kubo, H. and Achen, M. G. (2001). VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat. Med. 7, 186-191.
35. Title, J. C., Wood, J., Mandriota, S. J., Schnell, C., Ferrari, S., Mestan, J., Zhu, Z., Witte, L. and Pepper, M. S. (2001). Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro. J. Pharmacol. Exp. Ther. 299, 1073-1085.
36. ΔNΔC and VEGF-A-induced angiogenesis in vitro. Exp. Cell. Res. 285, 286-298.
37. Valtola, R., Salven, P., Heikkila, P., Thipale, J., Joensuu, H., Rehn, M., Pihlajaniemi, T., Weich, H., deWaal, R. and Alitalo, K. (1999). VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am. J. Pathol, 154, 1381-1390.
38. Veikkola, T., Jussila, L., Makinen, T., Karpanen, T., Jeltsch, M., Petrova, T. V., Kubo, H., Thurston, G., McDonald, D. M., Achen, M. G. et al. (2001). Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J. 20, 1223-1231.
39. Veikkola, T., Lohela, M., Ikenberg, K., Makinen, T., Korff, T., Saaristo, A., Petrova, T., Jeltsch, M., Augustin, H. G. and Alitalo, K. (2003). Intrinsic versus microenvironmental regulation of lymphatic endothelial cell phenotype and function. FASEB J. 17, 2006-2013.
40. Wang, J. F., Zhang, X. F. and Groopman, J. E. (2001). Stimulation of beta 1 integrin induces tyrosine phosphorylation of vascular endothelial growth factor receptor-3 and modulates cell migration. J. Biol. Chem. 276, 41950-41957.
41. Wigle, J. T. and Oliver, G. (1999). Prox1 function is required for the development of the murine lymphatic system. Cell 98, 769-778.
42. Witmer, A. N., van Blijswijk, B. C., Dai, J., Holman, P., Partanen, T. A., Vrensen, G. F. and Schlingemann, R. O. (2001). VEGFR-3 in adult angiogenesis. J. Pathol. 195, 490-497.
43. Zhu, Z., Rockwell, P., Lu, D., Kotanides, H., Pytowski, B., Hicklin, D. J., Bohlen, P. and Witte, L. (1998). Inhibition of vascular endothelial growth factor-induced receptor activation with anti-kinase insert domain-containing receptor single-chain antibodies from a phage display library. Cancer Res. 58, 3209-3214.
44. Zhu, Z., Bohlen, P. and Witte, L. (2002). Clinical development of angiogenesis inhibitors to vascular endothelial growth factor and its receptors as cancer therapeutics. Curr. Cancer Drug Targets 2, 135-156.
45. Zhu, Z., Hattori, K., Zhang, H., Jimenez, X., Ludwig, D. L., Dias, S., Kussie, P., Koo, H., Kim, H. J., Lu, D. et al. (2003). Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity. Leukemia 17, 604-611.